In Vivo Glycobiology Disease Model Screening Service
Revolutionizing Glycobiology Disease Research with Advanced In Vivo Models
Glycobiology disease is the disease caused by abnormal glycosylation of proteins or lipids, which can involve multiple organs such as the nervous, digestive, hematopoietic, and reproductive systems, resulting in a wide range of clinical manifestations. Animal models are the most commonly used tool for researching the pathogenesis of glycobiology disease and for drug screening, as they provide a complex biological system that mimics human disease.
At CD BioGlyco, we are engaged in the development of Glycobiology Disease Models over a long period and provide various types of glycobiology disease models and in vivo and in vitro glycobiology disease model screening services to our clients.
Here, we provide in vivo glycobiology disease model screening services as shown below.
- Spontaneous animal models
We obtain animals with spontaneous glycobiology disease by inbreeding them with animals predisposed to glycobiology disease under unintentionally artificial conditions. This method is commonly used in research on diabetic complications as well as genetic screening.
For example, we conduct sibling inbreeding of wild mice and introduce the obesity AY gene to the resulting breed, and the mouse shows obvious abnormalities of glucose tolerance and is accompanied by features such as high blood glucose, urinary glucose, and obesity. Thus, this model can be used not only to research the pathogenesis of diabetes but also to screen for genes or biomarkers associated with diabetes.
- Chemically induced animal models
The cytotoxicity of certain chemicals may cause direct or indirect damage to the pancreatic islet cells, resulting in insufficient insulin secretion and symptoms such as hyperglycemia and glucose intolerance. In our modeling, metabolic disorders are usually induced by a high-glucose diet, followed by injection of an appropriate amount of drugs to induce the occurrence of glycobiology disease, which can effectively shorten the construction cycle of animal models.
- Transgenic animal models
We use gene engineering techniques to introduce exogenous genes into the early embryo of an animal and integrate them into the animal's genes. In the process, we use gene engineering techniques to knock out, knock-in, or replace genes associated with glycobiology disease and allow them to be bred stably for several generations to obtain transgenic animals associated with glycobiology disease. The resulting animal is a good and stable model that can be used to screen for specific glycobiology disease-associated genes.
For example, MKR transgenic mice have impaired skeletal muscle-specific insulin-like growth factor-1 receptor function, and the impaired insulin receptor in vivo leads to insulin secretion disorders and exhibits typical diabetic features of lipid metabolism disorders. Therefore, it is a good and stable animal model for effective screening of diabetes-related genes.
![The flowchart of in vivo animal models screening service. (CD BioGlyco)](https://www.bioglyco.com/wp-content/themes/glycobio/img/4-16-4-in-vivo-glycobiology-disease-model-screening-service-1.jpg)
In addition, depending on the type of animal, we offer animal models that include but are not limited to the following.
The high degree of gaenetic similarity between vertebrates and humans greatly reduces modeling time, making it a good model for simulating human diseases. CD BioGlyco uses gene editing technology, represented by CRISPR/Cas9, to construct various types of vertebrate models for screening genes for glycobiology disease and use them to target genes or biomarkers for in vivo screening. Currently, we have developed a variety of vertebrate models.
- Mice Model
- Frog Model (Xenopus laevis)
- Rhesus Monkey Model
- Dog Model
- Rat Model
- Pig Model
- Rabbit Model
- Sheep Model
- Zebrafish Model
- Marmoset Model
- Humanized Mice Model
With a short lifespan, invertebrates have the advantage of being quick to model, easy to observe in culture, and can mimic multi-cellular environments and multi-tissue interactions. CD BioGlyco utilizes gene knockout and other methods to develop in vivo animal models for our clients for research on the pathogenesis of glycobiology disease and screening of disease genes for related diseases.
The invertebrate models we provide to our clients include but are not limited to, the following types.
- Drosophila Melanogaster Model
- Silkworm Model
- Caenorhabditis Elegans Model
- Bee Model
In addition to the vertebrate and invertebrate models mentioned above, many special animals can be used as research models for glycobiology disease. With the accumulated experience in the field of glycobiology disease model research and a first-class research team, CD BioGlyco provides clients with special animal models including but not limited to:
- Humanized Mice Model
- Hydra Model
- Alligator Model
- Leech Model
- Sea Anemone Model
- Marine Worm Model
Publication Data
Technology: Rodent model
Journal: International Journal of Molecular Sciences
IF: 5.6
Published: 2022
Results: Diabetes mellitus is a common endocrine disorder characterized by hyperglycemia. In this paper, the authors found a potential association between acrylamide (AA) and the prevalence of diabetes in the general population through in-depth research. In rats, AA promotes pancreatic islet remodeling and also induces changes in blood glucose in the body. In rodent models, AA impairs glucose metabolism and insulin signaling pathways. Rodents with diabetes were more sensitive to AA and AA exacerbated the diabetic state.
Fig.1 Comparative plot of insulin and glucagon staining in control and AA-treated rats. (Filipović, et al., 2022)
Frequently Asked Questions
- What is an in vivo animal model?
In vivo animal models are animal subjects used in medical research to simulate human diseases. These models can help scientists better understand the laws of disease occurrence and development, and research preventive and curative measures. Based on the cause of generation, animal models can be classified as induced, spontaneous, disease-resistant, and biomedical animal models. In addition, they can be classified according to the system scope or type of model, such as whole animals, isolated organs and tissues, cell lines, and mathematical models.
- What are the general steps in screening for disease genes in animal models?
- Developing animal models for specific diseases: Selecting suitable animal species and developing animal models that can simulate the characteristics of human diseases using gene engineering, chemical induction, or natural onset.
- Disease gene screening: Knockout, knock-in, and silencing of specific genes in the animal model through gene editing, observing their effects on the disease model, and screening out the target genes.
- Effectiveness evaluation: Detailed biological evaluation of the screened disease genes, such as the pathogenesis of the disease caused by the genes.
Advantages
- With rich experience in constructing glycobiology disease models and first-class biological technology, we provide custom in vivo animal models to solve the problems encountered in research.
- We offer a wide range of glycobiology disease models, covering both in vivo and in vitro, to ensure client satisfaction.
- Throughout the in vivo glycobiology disease model screening research, our R&D team maintains close technical communication with our clients to make the project progress smoothly.
CD BioGlyco utilizes years of expertise in glycobiology disease models to provide state-of-the-art in vivo animal model construction and disease screening solutions. We use our advanced resources and expertise to facilitate biological research and innovation for a wide range of clients. Please feel free to contact us for more information on the glycobiological disease model.
Reference
- Filipović, J.M.; et al. Acrylamide and potential risk of diabetes mellitus: effects on human population, glucose metabolism and beta-cell toxicity. International Journal of Molecular Sciences. 2022, 23(11): 6112.
This service is for Research Use Only, not intended for any clinical use.